Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
$595.5K
9 trades · 3 insiders
Net · 90d
$-595.5K
Insiders on file
15
Daily buy vs sell · 90 days
■ Open-market buys (P) ■ Open-market sales (S) · daily dollar value by transaction date
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Violette Shelia M. | Chief Scientific Officer | 24 | $0 | $118.4K | 2026-10-06 |
| Kalowski Lee | CFO and President | 14 | $0 | $199.4K | 2026-10-06 |
| Morrison Jodie Pope | CEO, Director | 18 | $0 | $494.3K | 2026-10-06 |
| Manke Isaac | Director | 14 | $0 | $0 | 2026-06-30 |
| Xu Diyong | Director, 10% Owner | 8 | $15.00M | $0 | 2026-06-12 |
| GRAYZEL DAVID S. | Director | 13 | $0 | $0 | 2026-06-12 |
| Lundberg Sven Ante | Director | 18 | $0 | $0 | 2026-06-12 |
| TZIANABOS ARTHUR | Director | 11 | $0 | $6.4K | 2026-06-12 |
| Iwicki Mark T | Director | 10 | $0 | $0 | 2026-06-12 |
| Thistle Mary | Director | 6 | $0 | $0 | 2026-06-12 |
| LAPORTE KATHLEEN | Director | 11 | $0 | $0 | 2026-06-12 |
| OrbiMed Capital GP VII LLC | Director, 10% Owner | 2 | $15.00M | $0 | 2026-05-28 |
| Campagna Jason | Chief Medical Officer | 8 | $0 | $0 | 2025-02-24 |
| Michaud Charles Jr | See Remarks | 1 | $0 | $1.8K | 2024-03-25 |
| Alloway Paul | See Remarks | 1 | $0 | $6.5K | 2024-03-25 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| Violette Shelia M. | Chief Scientific Officer | S Sale | 2026-10-06 | 2026-10-14 | 917 | $8.32 | $7.6K | 126,854 | SEC↗ |
| Morrison Jodie Pope | CEO, Director | S Sale | 2026-10-06 | 2026-10-14 | 3,221 | $8.32 | $26.8K | 340,038 | SEC↗ |
| Kalowski Lee | CFO and President | S Sale | 2026-10-06 | 2026-10-14 | 1,301 | $8.32 | $10.8K | 137,170 | SEC↗ |
| Violette Shelia M. | Chief Scientific Officer | S Sale | 2026-08-25 | 2026-08-27 | 2,798 | $16.56 | $46.3K | 127,771 | SEC↗ |
| Kalowski Lee | CFO and President | S Sale | 2026-08-25 | 2026-08-27 | 3,972 | $16.56 | $65.8K | 138,471 | SEC↗ |
| Morrison Jodie Pope | CEO | S Sale | 2026-08-25 | 2026-08-27 | 9,845 | $16.56 | $163.0K | 343,259 | SEC↗ |
| Violette Shelia M. | Chief Scientific Officer | S Sale | 2026-08-25 | 2026-08-27 | 2,798 | $16.56 | $46.3K | 127,771 | SEC↗ |
| Morrison Jodie Pope | CEO, Director | S Sale | 2026-08-25 | 2026-08-27 | 9,845 | $16.56 | $163.0K | 343,259 | SEC↗ |
| Kalowski Lee | CFO and President | S Sale | 2026-08-25 | 2026-08-27 | 3,972 | $16.56 | $65.8K | 138,471 | SEC↗ |
| Kalowski Lee | CFO and President | A Award | 2026-07-16 | 2026-07-20 | 53,250 | — | $0 | 142,443 | SEC↗ |
| Morrison Jodie Pope | CEO | A Award | 2026-07-16 | 2026-07-20 | 132,000 | — | $0 | 353,104 | SEC↗ |
| Violette Shelia M. | Chief Scientific Officer | A Award | 2026-07-16 | 2026-07-20 | 37,500 | — | $0 | 130,569 | SEC↗ |
| Manke Isaac | Director | M Exercise deriv | 2026-06-30 | 2026-07-02 | 53,521 | — | $0 | 0 | SEC↗ |
| Manke Isaac | Director | M Exercise | 2026-06-30 | 2026-07-02 | 53,521 | $2.80 | $149.9K | 53,521 | SEC↗ |
| Thistle Mary | Director | A Award deriv | 2026-06-12 | 2026-07-21 | 10,826 | — | $0 | 10,826 | SEC↗ |
| GRAYZEL DAVID S. | Director | A Award deriv | 2026-06-12 | 2026-07-21 | 10,826 | — | $0 | 10,826 | SEC↗ |
| Manke Isaac | Director | A Award deriv | 2026-06-12 | 2026-07-21 | 10,826 | — | $0 | 10,826 | SEC↗ |
| Xu Diyong | Director, 10% Owner | A Award deriv | 2026-06-12 | 2026-07-21 | 10,826 | — | $0 | 10,826 | SEC↗ |
| Iwicki Mark T | Director | A Award deriv | 2026-06-12 | 2026-07-21 | 10,826 | — | $0 | 10,826 | SEC↗ |
| LAPORTE KATHLEEN | Director | A Award deriv | 2026-06-12 | 2026-07-21 | 10,826 | — | $0 | 10,826 | SEC↗ |
| Lundberg Sven Ante | Director | A Award deriv | 2026-06-12 | 2026-07-21 | 10,826 | — | $0 | 10,826 | SEC↗ |
| TZIANABOS ARTHUR | Director | A Award deriv | 2026-06-12 | 2026-07-21 | 10,826 | — | $0 | 10,826 | SEC↗ |
| Lundberg Sven Ante | Director | A Award deriv | 2026-06-12 | 2026-06-16 | 9,810 | — | $0 | 9,810 | SEC↗ |
| Xu Diyong | Director, 10% Owner | A Award deriv | 2026-06-12 | 2026-06-16 | 9,810 | — | $0 | 9,810 | SEC↗ |
| Thistle Mary | Director | A Award deriv | 2026-06-12 | 2026-06-16 | 9,810 | — | $0 | 9,810 | SEC↗ |
| GRAYZEL DAVID S. | Director | A Award deriv | 2026-06-12 | 2026-06-16 | 9,810 | — | $0 | 9,810 | SEC↗ |
| Manke Isaac | Director | A Award deriv | 2026-06-12 | 2026-06-16 | 9,810 | — | $0 | 9,810 | SEC↗ |
| TZIANABOS ARTHUR | Director | A Award deriv | 2026-06-12 | 2026-06-16 | 9,810 | — | $0 | 9,810 | SEC↗ |
| Iwicki Mark T | Director | A Award deriv | 2026-06-12 | 2026-06-16 | 9,810 | — | $0 | 9,810 | SEC↗ |
| LAPORTE KATHLEEN | Director | A Award deriv | 2026-06-12 | 2026-06-16 | 9,810 | — | $0 | 9,810 | SEC↗ |
| OrbiMed Capital GP VII LLC | Director, 10% Owner | P Buy | 2026-05-28 | 2026-06-01 | 1,250,000 | $8.00 | $10.00M | 3,502,987 | SEC↗ |
| OrbiMed Capital GP VII LLC | Director, 10% Owner | P Buy | 2026-05-28 | 2026-06-01 | 625,000 | $8.00 | $5.00M | 625,000 | SEC↗ |
| Xu Diyong | Director, 10% Owner | P Buy | 2026-05-28 | 2026-06-01 | 625,000 | $8.00 | $5.00M | 625,000 | SEC↗ |
| Xu Diyong | Director, 10% Owner | P Buy | 2026-05-28 | 2026-06-01 | 1,250,000 | $8.00 | $10.00M | 3,502,987 | SEC↗ |
| Violette Shelia M. | Chief Scientific Officer | S Sale | 2026-02-25 | 2026-02-27 | 2,815 | $4.51 | $12.7K | 55,569 | SEC↗ |
| Morrison Jodie Pope | CEO | S Sale | 2026-02-25 | 2026-02-27 | 9,896 | $4.51 | $44.6K | 89,104 | SEC↗ |
| Kalowski Lee | CFO and President | S Sale | 2026-02-25 | 2026-02-27 | 3,995 | $4.51 | $18.0K | 35,943 | SEC↗ |
| Kalowski Lee | CFO and President | A Award | 2026-02-24 | 2026-03-20 | 53,250 | — | $0 | 89,193 | SEC↗ |
| Morrison Jodie Pope | CEO | A Award | 2026-02-24 | 2026-03-20 | 132,000 | — | $0 | 221,104 | SEC↗ |
| Violette Shelia M. | Chief Scientific Officer | A Award | 2026-02-24 | 2026-03-20 | 37,500 | — | $0 | 93,069 | SEC↗ |
| Lundberg Sven Ante | Director | A Award deriv | 2026-01-15 | 2026-01-30 | 20,363 | $2.75 | $56.0K | 20,363 | SEC↗ |
| GRAYZEL DAVID S. | Director | A Award deriv | 2026-01-15 | 2026-01-30 | 16,363 | $2.75 | $45.0K | 16,363 | SEC↗ |
| LAPORTE KATHLEEN | Director | A Award deriv | 2026-01-15 | 2026-01-30 | 23,272 | $2.75 | $64.0K | 23,272 | SEC↗ |
| Kalowski Lee | CFO and President | S Sale | 2025-12-02 | 2025-12-04 | 9,072 | $3.46 | $31.4K | 39,938 | SEC↗ |
| Morrison Jodie Pope | CEO | S Sale | 2025-12-02 | 2025-12-04 | 22,506 | $3.46 | $77.9K | 99,000 | SEC↗ |
| LAPORTE KATHLEEN | Director | A Award deriv | 2025-10-23 | 2025-10-27 | 53,521 | — | $0 | 53,521 | SEC↗ |
| TZIANABOS ARTHUR | Director | A Award deriv | 2025-10-23 | 2025-10-27 | 53,521 | — | $0 | 53,521 | SEC↗ |
| GRAYZEL DAVID S. | Director | A Award deriv | 2025-10-23 | 2025-10-27 | 53,521 | — | $0 | 53,521 | SEC↗ |
| Thistle Mary | Director | A Award deriv | 2025-10-23 | 2025-10-27 | 53,521 | — | $0 | 53,521 | SEC↗ |
| Xu Diyong | Director | A Award deriv | 2025-10-23 | 2025-10-27 | 53,521 | — | $0 | 53,521 | SEC↗ |
| Manke Isaac | Director | A Award deriv | 2025-10-23 | 2025-10-27 | 53,521 | — | $0 | 53,521 | SEC↗ |
| Iwicki Mark T | Director | A Award deriv | 2025-10-23 | 2025-10-27 | 53,521 | — | $0 | 53,521 | SEC↗ |
| Lundberg Sven Ante | Director | A Award deriv | 2025-10-23 | 2025-10-27 | 53,521 | — | $0 | 53,521 | SEC↗ |
| Kalowski Lee | CFO and President | S Sale | 2025-08-26 | 2025-08-28 | 4,240 | $1.80 | $7.6K | 49,010 | SEC↗ |
| Violette Shelia M. | Chief Scientific Officer | S Sale | 2025-08-26 | 2025-08-28 | 2,990 | $1.80 | $5.4K | 58,384 | SEC↗ |
| Morrison Jodie Pope | CEO | S Sale | 2025-08-26 | 2025-08-28 | 10,494 | $1.80 | $18.9K | 121,506 | SEC↗ |
| Lundberg Sven Ante | Director | A Award deriv | 2025-02-24 | 2025-02-26 | 12,767 | — | $0 | 12,767 | SEC↗ |
| Lundberg Sven Ante | Director | D To issuer deriv | 2025-02-24 | 2025-02-26 | 2,013 | — | $0 | 0 | SEC↗ |
| Lundberg Sven Ante | Director | A Award deriv | 2025-02-24 | 2025-02-26 | 23,140 | — | $0 | 23,140 | SEC↗ |
| Lundberg Sven Ante | Director | D To issuer deriv | 2025-02-24 | 2025-02-26 | 23,140 | — | $0 | 0 | SEC↗ |
| Lundberg Sven Ante | Director | D To issuer deriv | 2025-02-24 | 2025-02-26 | 1,316 | — | $0 | 0 | SEC↗ |
| Lundberg Sven Ante | Director | A Award deriv | 2025-02-24 | 2025-02-26 | 2,013 | — | $0 | 2,013 | SEC↗ |
| Lundberg Sven Ante | Director | D To issuer deriv | 2025-02-24 | 2025-02-26 | 12,767 | — | $0 | 0 | SEC↗ |
| Lundberg Sven Ante | Director | A Award deriv | 2025-02-24 | 2025-02-26 | 2,880 | — | $0 | 2,880 | SEC↗ |
| Lundberg Sven Ante | Director | D To issuer deriv | 2025-02-24 | 2025-02-26 | 2,880 | — | $0 | 0 | SEC↗ |
| Lundberg Sven Ante | Director | A Award deriv | 2025-02-24 | 2025-02-26 | 6,238 | — | $0 | 6,238 | SEC↗ |
| Lundberg Sven Ante | Director | D To issuer deriv | 2025-02-24 | 2025-02-26 | 6,238 | — | $0 | 0 | SEC↗ |
| Violette Shelia M. | Chief Scientific Officer | A Award deriv | 2025-02-24 | 2025-02-26 | 56,413 | — | $0 | 56,413 | SEC↗ |
| Violette Shelia M. | Chief Scientific Officer | D To issuer deriv | 2025-02-24 | 2025-02-26 | 13,305 | — | $0 | 0 | SEC↗ |
| Violette Shelia M. | Chief Scientific Officer | A Award deriv | 2025-02-24 | 2025-02-26 | 32,891 | — | $0 | 32,891 | SEC↗ |
| Violette Shelia M. | Chief Scientific Officer | D To issuer deriv | 2025-02-24 | 2025-02-26 | 32,891 | — | $0 | 0 | SEC↗ |
| Violette Shelia M. | Chief Scientific Officer | A Award deriv | 2025-02-24 | 2025-02-26 | 13,305 | — | $0 | 13,305 | SEC↗ |
| Violette Shelia M. | Chief Scientific Officer | D To issuer deriv | 2025-02-24 | 2025-02-26 | 56,413 | — | $0 | 0 | SEC↗ |
| Violette Shelia M. | Chief Scientific Officer | A Award deriv | 2025-02-24 | 2025-02-26 | 17,506 | — | $0 | 17,506 | SEC↗ |
| Violette Shelia M. | Chief Scientific Officer | D To issuer deriv | 2025-02-24 | 2025-02-26 | 17,506 | — | $0 | 0 | SEC↗ |
| Thistle Mary | Director | D To issuer deriv | 2025-02-24 | 2025-02-26 | 12,767 | — | $0 | 0 | SEC↗ |
| Thistle Mary | Director | A Award deriv | 2025-02-24 | 2025-02-26 | 12,767 | — | $0 | 12,767 | SEC↗ |
| GRAYZEL DAVID S. | Director | A Award deriv | 2025-02-24 | 2025-02-26 | 2,569 | — | $0 | 2,569 | SEC↗ |
| GRAYZEL DAVID S. | Director | A Award deriv | 2025-02-24 | 2025-02-26 | 18,595 | — | $0 | 18,595 | SEC↗ |
| GRAYZEL DAVID S. | Director | A Award deriv | 2025-02-24 | 2025-02-26 | 12,767 | — | $0 | 12,767 | SEC↗ |
| GRAYZEL DAVID S. | Director | D To issuer deriv | 2025-02-24 | 2025-02-26 | 12,767 | — | $0 | 0 | SEC↗ |
| GRAYZEL DAVID S. | Director | D To issuer deriv | 2025-02-24 | 2025-02-26 | 18,595 | — | $0 | 0 | SEC↗ |
| GRAYZEL DAVID S. | Director | D To issuer deriv | 2025-02-24 | 2025-02-26 | 2,569 | — | $0 | 0 | SEC↗ |
| Campagna Jason | Chief Medical Officer | A Award deriv | 2025-02-24 | 2025-02-26 | 70,687 | — | $0 | 70,687 | SEC↗ |
| Campagna Jason | Chief Medical Officer | D To issuer deriv | 2025-02-24 | 2025-02-26 | 87,738 | — | $0 | 0 | SEC↗ |
| Campagna Jason | Chief Medical Officer | A Award deriv | 2025-02-24 | 2025-02-26 | 87,738 | — | $0 | 87,738 | SEC↗ |
| Campagna Jason | Chief Medical Officer | D To issuer deriv | 2025-02-24 | 2025-02-26 | 17,951 | — | $0 | 0 | SEC↗ |
| Campagna Jason | Chief Medical Officer | A Award deriv | 2025-02-24 | 2025-02-26 | 17,951 | — | $0 | 17,951 | SEC↗ |
| Campagna Jason | Chief Medical Officer | D To issuer deriv | 2025-02-24 | 2025-02-26 | 70,687 | — | $0 | 0 | SEC↗ |
| Iwicki Mark T | Director | A Award deriv | 2025-02-24 | 2025-02-26 | 25,534 | — | $0 | 25,534 | SEC↗ |
| Iwicki Mark T | Director | D To issuer deriv | 2025-02-24 | 2025-02-26 | 37,222 | — | $0 | 0 | SEC↗ |
| Iwicki Mark T | Director | A Award deriv | 2025-02-24 | 2025-02-26 | 37,222 | — | $0 | 37,222 | SEC↗ |
| Iwicki Mark T | Director | D To issuer deriv | 2025-02-24 | 2025-02-26 | 7,615 | — | $0 | 0 | SEC↗ |
| Iwicki Mark T | Director | A Award deriv | 2025-02-24 | 2025-02-26 | 7,615 | — | $0 | 7,615 | SEC↗ |
| Iwicki Mark T | Director | D To issuer deriv | 2025-02-24 | 2025-02-26 | 25,534 | — | $0 | 0 | SEC↗ |
| Xu Diyong | Director | D To issuer deriv | 2025-02-24 | 2025-02-26 | 12,767 | — | $0 | 0 | SEC↗ |
| Xu Diyong | Director | A Award deriv | 2025-02-24 | 2025-02-26 | 12,767 | — | $0 | 12,767 | SEC↗ |
| Morrison Jodie Pope | CEO | D To issuer deriv | 2025-02-24 | 2025-02-26 | 394,445 | — | $0 | 0 | SEC↗ |
| Morrison Jodie Pope | CEO | D To issuer deriv | 2025-02-24 | 2025-02-26 | 152,700 | — | $0 | 0 | SEC↗ |
| Morrison Jodie Pope | CEO | A Award deriv | 2025-02-24 | 2025-02-26 | 152,700 | — | $0 | 152,700 | SEC↗ |
| Morrison Jodie Pope | CEO | D To issuer deriv | 2025-02-24 | 2025-02-26 | 152,700 | — | $0 | 0 | SEC↗ |
| Morrison Jodie Pope | CEO | A Award deriv | 2025-02-24 | 2025-02-26 | 152,700 | — | $0 | 152,700 | SEC↗ |
| Morrison Jodie Pope | CEO | D To issuer deriv | 2025-02-24 | 2025-02-26 | 16,901 | — | $0 | 0 | SEC↗ |
| Morrison Jodie Pope | CEO | A Award deriv | 2025-02-24 | 2025-02-26 | 16,901 | — | $0 | 16,901 | SEC↗ |
| Morrison Jodie Pope | CEO | A Award deriv | 2025-02-24 | 2025-02-26 | 394,445 | — | $0 | 394,445 | SEC↗ |
| TZIANABOS ARTHUR | Director | A Award deriv | 2025-02-24 | 2025-02-27 | 12,767 | — | $0 | 12,767 | SEC↗ |
| TZIANABOS ARTHUR | Director | D To issuer deriv | 2025-02-24 | 2025-02-27 | 12,767 | — | $0 | 0 | SEC↗ |
| TZIANABOS ARTHUR | Director | A Award deriv | 2025-02-24 | 2025-02-27 | 25,674 | — | $0 | 25,674 | SEC↗ |
| TZIANABOS ARTHUR | Director | D To issuer deriv | 2025-02-24 | 2025-02-27 | 25,674 | — | $0 | 0 | SEC↗ |
| LAPORTE KATHLEEN | Director | A Award deriv | 2025-02-24 | 2025-02-27 | 5,431 | — | $0 | 5,431 | SEC↗ |
| LAPORTE KATHLEEN | Director | D To issuer deriv | 2025-02-24 | 2025-02-27 | 5,431 | — | $0 | 0 | SEC↗ |
| LAPORTE KATHLEEN | Director | D To issuer deriv | 2025-02-24 | 2025-02-27 | 1,947 | — | $0 | 0 | SEC↗ |
| LAPORTE KATHLEEN | Director | A Award deriv | 2025-02-24 | 2025-02-27 | 1,947 | — | $0 | 1,947 | SEC↗ |
| LAPORTE KATHLEEN | Director | A Award deriv | 2025-02-24 | 2025-02-27 | 12,767 | — | $0 | 12,767 | SEC↗ |
| LAPORTE KATHLEEN | Director | D To issuer deriv | 2025-02-24 | 2025-02-27 | 12,767 | — | $0 | 0 | SEC↗ |
| Kalowski Lee | CFO and President | A Award deriv | 2025-02-24 | 2025-02-27 | 16,901 | — | $0 | 16,901 | SEC↗ |
| Kalowski Lee | CFO and President | D To issuer deriv | 2025-02-24 | 2025-02-27 | 16,901 | — | $0 | 0 | SEC↗ |
| Kalowski Lee | CFO and President | D To issuer deriv | 2025-02-24 | 2025-02-27 | 161,323 | — | $0 | 0 | SEC↗ |
| Kalowski Lee | CFO and President | A Award deriv | 2025-02-24 | 2025-02-27 | 161,323 | — | $0 | 161,323 | SEC↗ |
| Manke Isaac | Director | A Award deriv | 2025-02-24 | 2025-02-27 | 12,767 | — | $0 | 12,767 | SEC↗ |
| Manke Isaac | Director | D To issuer deriv | 2025-02-24 | 2025-02-27 | 19,008 | — | $0 | 0 | SEC↗ |
| Manke Isaac | Director | D To issuer deriv | 2025-02-24 | 2025-02-27 | 2,627 | — | $0 | 0 | SEC↗ |
| Manke Isaac | Director | A Award deriv | 2025-02-24 | 2025-02-27 | 19,008 | — | $0 | 19,008 | SEC↗ |
| Manke Isaac | Director | D To issuer deriv | 2025-02-24 | 2025-02-27 | 12,767 | — | $0 | 0 | SEC↗ |
| Manke Isaac | Director | A Award deriv | 2025-02-24 | 2025-02-27 | 2,627 | — | $0 | 2,627 | SEC↗ |
| Violette Shelia M. | Chief Scientific Officer | A Award | 2025-02-24 | 2025-02-26 | 37,500 | — | $0 | 61,374 | SEC↗ |
| Campagna Jason | Chief Medical Officer | A Award | 2025-02-24 | 2025-02-26 | 37,500 | — | $0 | 37,500 | SEC↗ |
| Morrison Jodie Pope | CEO | A Award | 2025-02-24 | 2025-02-26 | 132,000 | — | $0 | 132,000 | SEC↗ |
| Kalowski Lee | CFO and President | A Award | 2025-02-24 | 2025-02-27 | 53,250 | — | $0 | 53,250 | SEC↗ |
| Lundberg Sven Ante | Director | A Award deriv | 2025-01-15 | 2025-02-26 | 23,140 | — | $0 | 23,140 | SEC↗ |
| GRAYZEL DAVID S. | Director | A Award deriv | 2025-01-15 | 2025-02-26 | 18,595 | — | $0 | 18,595 | SEC↗ |
| Manke Isaac | Director | A Award deriv | 2025-01-15 | 2025-02-27 | 19,008 | — | $0 | 19,008 | SEC↗ |
| Violette Shelia M. | Chief Scientific Officer | M Exercise deriv | 2024-10-15 | 2024-10-16 | 6,000 | — | $0 | 32,891 | SEC↗ |
| Violette Shelia M. | Chief Scientific Officer | M Exercise | 2024-10-15 | 2024-10-16 | 6,000 | $7.29 | $43.7K | 23,874 | SEC↗ |
| Violette Shelia M. | Chief Scientific Officer | M Exercise deriv | 2024-10-11 | 2024-10-16 | 213 | — | $0 | 0 | SEC↗ |
| Violette Shelia M. | Chief Scientific Officer | M Exercise deriv | 2024-10-11 | 2024-10-16 | 4,361 | — | $0 | 0 | SEC↗ |
| Violette Shelia M. | Chief Scientific Officer | M Exercise | 2024-10-11 | 2024-10-16 | 4,574 | $3.12 | $14.3K | 17,874 | SEC↗ |
| Violette Shelia M. | Chief Scientific Officer | M Exercise deriv | 2024-10-08 | 2024-10-10 | 13,300 | — | $0 | 213 | SEC↗ |
| Violette Shelia M. | Chief Scientific Officer | M Exercise | 2024-10-08 | 2024-10-10 | 13,300 | $3.12 | $41.5K | 13,300 | SEC↗ |
| Lundberg Sven Ante | Director | A Award deriv | 2024-09-25 | 2024-09-27 | 1,316 | — | $0 | 1,316 | SEC↗ |
| GRAYZEL DAVID S. | Director | A Award deriv | 2024-04-01 | 2024-08-14 | 2,569 | $13.42 | $34.5K | 2,569 | SEC↗ |
| Manke Isaac | Director | A Award deriv | 2024-04-01 | 2024-09-30 | 2,627 | $13.42 | $35.3K | 2,627 | SEC↗ |
| TZIANABOS ARTHUR | Director | M Exercise deriv | 2024-03-25 | 2024-08-14 | 1,095 | — | $0 | 0 | SEC↗ |
| TZIANABOS ARTHUR | Director | S Sale | 2024-03-25 | 2024-08-14 | 265 | $24.20 | $6.4K | 7,983 | SEC↗ |
| TZIANABOS ARTHUR | Director | M Exercise | 2024-03-25 | 2024-08-14 | 1,095 | — | $0 | 8,248 | SEC↗ |
| Michaud Charles Jr | See Remarks | S Sale | 2024-03-25 | 2024-04-23 | 75 | $24.20 | $1.8K | 927 | SEC↗ |
| Alloway Paul | See Remarks | S Sale | 2024-03-25 | 2024-04-23 | 268 | $24.21 | $6.5K | 2,596 | SEC↗ |
| Lundberg Sven Ante | Director | A Award deriv | 2024-03-25 | 2024-03-27 | 12,767 | — | $0 | 12,767 | SEC↗ |
| Thistle Mary | Director | A Award deriv | 2024-03-25 | 2024-03-27 | 12,767 | — | $0 | 12,767 | SEC↗ |
| Kalowski Lee | CFO and President | A Award deriv | 2024-03-25 | 2024-03-27 | 161,323 | — | $0 | 161,323 | SEC↗ |
| LAPORTE KATHLEEN | Director | A Award deriv | 2024-03-25 | 2024-03-27 | 12,767 | — | $0 | 12,767 | SEC↗ |
| Violette Shelia M. | Chief Scientific Officer | A Award deriv | 2024-03-25 | 2024-03-27 | 56,413 | — | $0 | 56,413 | SEC↗ |
| Morrison Jodie Pope | CEO | A Award deriv | 2024-03-25 | 2024-03-27 | 394,445 | — | $0 | 394,445 | SEC↗ |
| Campagna Jason | Chief Medical Officer | A Award deriv | 2024-03-25 | 2024-03-27 | 70,687 | — | $0 | 70,687 | SEC↗ |
| Xu Diyong | Director, 10% Owner | A Award deriv | 2024-03-25 | 2024-03-27 | 12,767 | — | $0 | 12,767 | SEC↗ |
| GRAYZEL DAVID S. | Director | A Award deriv | 2024-03-25 | 2024-03-27 | 12,767 | — | $0 | 12,767 | SEC↗ |
| Iwicki Mark T | Director | A Award deriv | 2024-03-25 | 2024-03-27 | 25,534 | — | $0 | 25,534 | SEC↗ |
| Manke Isaac | Director | A Award deriv | 2024-03-25 | 2024-03-27 | 12,767 | — | $0 | 12,767 | SEC↗ |
| TZIANABOS ARTHUR | Director | A Award deriv | 2024-03-25 | 2024-03-27 | 12,767 | — | $0 | 12,767 | SEC↗ |